New research in Pediatrics suggests that children who are exposed to antibiotics could have an increased risk of newly diagnosed juvenile idiopathic arthritis (JIA), but that antibiotic use could be a marker for abnormal immunity rather than a direct cause of JIA.
A drug used to treat rheumatoid arthritis (RA) was effective in patients with moderate to severe eczema, according to a study conducted by researchers from Yale School of Medicine.
Ipsen announced that the Food and Drug Administration (FDA) has approved Dysport (abobotulinumtoxinA) injection for the treatment of upper limb spasticity in adults.
Opioids are often prescribed to treat chronic lower back pain, but patients with comorbid psychiatric disorders such as depression and anxiety could experience significantly less pain relief with this therapy and may be more likely to abuse their medication.
The Food and Drug Administration (FDA) issued a warning about the potential risk of purchasing counterfeit diazepam online.
Pfizer announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Xeljanz (tofacitinib citrate) 11mg once daily modified release tablets for the treatment of moderate to severe rheumatoid arthritis in patients with inadequate response or intolerance to methotrexate.
Sarepta Therapeutics announced that it has completed a rolling submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for eteplirsen.
Novartis announced one year results from the Phase 3 FUTURE 2 study with Cosentyx (secukinumab) in patients with psoriatic arthritis (PsA).
Results from the National Health Interview Survey show that between 2008 and 2013, the percentage of people meeting the Department of Health and Human Services 2008 Physical Activity Guidelines for Americans increased for all age groups.
A study presented at the European League Against Rheumatism Annual Congress (EULAR 2015) indicates that use of some non-steroidal anti-inflammatory drugs (NSAIDs) could have a negative impact on female fertility, even with short-term use.
Mylan announced that it is expanding a voluntary recall of multiple injectable products to the hospital/user level due to the presence of visible foreign particulate matter.
A third of the world's population, about 2.3 billion people, is experiencing over five ailments, according to a new analysis from the Global Burden of Disease Study (GBD) 2013.
The Food and Drug Administration (FDA) has warning consumers to not buy or use GC Natural's Pyrola Advanced Joint Formula, an herbal supplement marketed for joint pain.
Prolonged wearing of high-heeled shoes has been linked to injuries related to the plantarflexor (PF) and dorsiflexor (DF), but a new study in the International Journal of Clinical Practice has also found that it may initially strengthen ankle muscles but eventually can lead to a muscular imbalance, a predictor of ankle injury.
Regeneron and Sanofi announced results from their Phase 3 SARIL-RA-TARGET trial of sarilumab in patients with rheumatoid arthritis (RA).
Osteo Bi-Flex announced the launch of Osteo Bi-Flex EASE, a mini-tab supplement that promotes joint comfort through a novel collagen-based formula.
A short course of oral steroids provided modest improvement in function and no significant improvement in pain for patients with acute radiculopathy (sciatica), a study published in JAMA has shown.
A new study has shown that treatment for overactive bladder (OAB) may lead to less falls among older adults.
Endo announced that the Food and Drug Administration (FDA) has approved a label update for Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture (DC) patients with a palpable cord.
Nevro announced that the Food and Drug Administration (FDA) has approved the Senza System, a spinal cord stimulation (SCS) system as an aid in the management of chronic intractable pain of the trunk and/or limbs, including pain associated with failed back surgery syndrome, low back pain, and leg pain.
Toxic levels of vitamin D are rarely seen in people taking supplements, according to Mayo Clinic researchers.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to Resolaris (aTyr Pharma), a physiocrine-based product for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
The FDA has approved an expansion of the Botox (onabotulinumtoxinA; Actavis) label for the treatment of adults with upper limb spasticity.
The FDA is warning pet owners, veterinarians, healthcare providers, and pharmacists that pets are at risk of illness and death when exposed to topical pain medications containing flurbiprofen.
The FDA is alerting healthcare providers and the public that counterfeit Botox (onabotulinumtoxin A; Allergan) has been found in the United States and may have been distributed to doctors' offices and clinics.
Contrary to popular advice, applying ice after a muscle impact injury may not contribute to angiogenesis and muscle regeneration and could actually delay recovery.
Celgene announced results from the ESTEEM Phase 3 clinical program for Otezla (apremilast) in patients with moderate to severe plaque psoriasis.
Eli Lilly and Company and Incyte announced results from a second Phase 3 trial with baricitinib in patients with rheumatoid arthritis.
Noven announced the launch of Minivelle (estradiol transdermal system) 0.025mg/day, a new low dosage strength approved for the prevention of postmenopausal osteoporosis.
Amgen announced results for its Phase 3 study evaluating the safety and efficacy of biosimilar candidate ABP 501 compared to adalimumab (Humira; AbbVie) in patients with moderate-to-severe rheumatoid arthritis.
The Food and Drug Administration (FDA) is recommending against the routine use of bone graft substitutes containing recombinant proteins or synthetic peptides in patients under 18 years old.
The Food and Drug Administration (FDA) has granted Fast Track designation to deflazacort (Marathon Pharmaceuticals) for the treatment of patients with Duchenne Muscular Dystrophy (DMD).
A new study shows that women who experience menopausal symptoms (eg, severe hot flashes, night sweats) tend to have lower bone mineral density and higher rates of hip fractures vs. women who do not have menopausal symptoms.
Crealta announced results from two Phase 3 trials and one open-label extension trial on loss of urate-lowering response to Krystexxa (pegloticase) and risk of infusion reactions cited in the product's Food and Drug Administration (FDA)-approved labeling.
Eli Lilly and Company and Incyte Corp. announced results from the Phase 3 RA-BEACON study of baricitinib in patients with active rheumatoid arthritis (RA).
A new drug could allow the long axons of spinal cord nerve cells to regenerate after paralyzing spinal cord injuries, unlike current treatments that may require touching the healing spinal cord.
According to a U.S. Census Bureau report, almost 40% of people ages ≥65 had at least one disability, of which two-thirds reported difficulty in walking or climbing.
The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dysport (abobotulinumtoxinA; Ipsen) for the treatment of upper limb spasticity in adults.
The Endocrine Society released a Clinical Practice Guideline for the diagnosis and treatment of Paget's disease of the bone.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to CAT-1004 (Catabasis) for the treatment of Duchenne Muscular Dystrophy (DMD).
The Food and Drug Administration (FDA) is warning consumers not to buy or use "Feng Shi Ling," a product marketed as an herbal drug for pain due to rheumatoid arthritis and osteoporosis.
Celgene announced results from two PALACE Phase 3 clinical trials with Otezla (apremilast) for the treatment of adults with active psoriatic arthritis and for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Novartis announced results from the Phase 3 FUTURE 1 and FUTURE 2 studies with secukinumab in patients with psoriatic arthritis (PsA).
Bristol-Myers Squibb Company announced results of several new sub-analyses of the Phase 3b AVERT trial investigating the use of Orencia (abatacept) plus methotrexate (MTX) in biologic and MTX-naïve CCP-positive early moderate to severe rheumatoid arthritis (RA) patients.
Men are three times less likely to undergo bone mass density (BMD) testing following a distal radial fracture compared to women, reports a new study.
Auxilium announced that the Food and Drug Administration (FDA) has approved Xiaflex (collagenase clostridium histolyticum) for the treatment of up to 2 Dupuytren's contracture joints in the same hand during a single treatment visit.
Medac Pharma announced the launch of Rasuvo (methotrexate) injection for patients with rheumatoid arthritis, polyarticular course juvenile idiopathic arthritis (pJIA), and psoriasis.
AbbVie announced that the Food and Drug Administration (FDA) has approved the use of Humira (adalimumab) for moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) to reducing signs and symptoms in patients aged ≥2 years.
AbbVie announced that the Food and Drug Administration (FDA) has approved Humira (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease for patients ≥6 years old.
Noven announced that the Food and Drug Administration (FDA) has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for the prevention of postmenopausal osteoporosis.
Celgene announced that the Food and Drug Administration (FDA) has approved Otezla (apremilast) for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
The American Orthopaedic Foot & Ankle Society (AOFAS) has released a list of tests and procedures that are commonly ordered but not always necessary.
Merck announced results from the Phase 3 LOFT study with odanacatib in postmenopausal women with osteoporosis.
Ampio announced an update to the Phase 3 multicenter, double-blind STEP study of Ampion for osteoarthritis (OA) of the knee.
Iroko announced that the Food and Drug Administration (FDA) has approved Zorvolex (diclofenac) capsules for the management of osteoarthritis pain.
Eagle Pharmaceuticals announced that the FDA has approved Ryanodex (dantrolene sodium) for injectable suspension, an antidote for the management of malignant hyperthermia (MH), along with the appropriate supportive measures.
American Health Packaging announced a voluntary recall of Ibuprofen Tablets 600mg and Oxcarbazepine Tables 300mg due to mislabeled inner unit dose blister packaging.
Medac Pharma announced that the FDA has approved Rasuvo (methotrexate) subcutaneous auto-injector for the management of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis (pJIA), and severe, recalcitrant, disabling psoriasis.
EarlySense has announced that the FDA has issued clearance for the Chair Sensor Solution, the first automatic contact-free sensor for continuous monitoring of patients' vital signs in a chair.
The FDA has cleared the first motorized device intended to act as an exoskeleton in individuals with paraplegia due to spinal cord injuries for use at home and in the community.
At EULAR 2014, scientists presented the possibility of using biomarkers to predict disease outcomes at 12 months in children with juvenile idiopathic arthritis (JIA).
Increased healthcare costs were associated with musculoskeletal disorders compared to other disease states, according to a new study presented at EULAR 2014.
Positions 11, 71, and 74 of the HLA-DRB1 gene was shown to be strong independent genetic determinants of radiological damage in rheumatoid arthritis (RA).
A potential biomarker of response to anti-TNF therapies in patients with rheumatoid arthritis (RA) has been identified, which could lead to the personalization of RA treatment.
Erectile dysfunction (ED) is present and frequently severe in most men with gout, reports research presented at the European League Against Rheumatism Annual Congress (EULAR 2014).
Cranial ultrasound is superior in sensitivity and has comparable specificity in the diagnosis of giant cell arteritis (GCA) compared to temporal artery biopsy (TAB), according to a new study.
At EULAR 2014, two studies shed insight on the relationship between dietary intake of monounsaturated fatty acids and cholesterol with disease activity in rheumatoid arthritis (RA) and osteoarthritis (OA), respectively.
CT-P13, an infliximab biosimilar, achieved statistically similar improvements in disease activity disability, and mobility in patients with ankylosing spondylitis (AS) compared to infliximab, results from the PLANETAS study found at EULAR 2014.
Romosozumab was found to significantly increase bone mineral density and bone content in the spine and hip in postmenopausal women compared to baseline and also compared to teriparatide and placebo, as presented at EULAR 2014.
Many patients with psoriatic arthritis were not receiving doses of TNFα inhibitor, adalimumab, to obtain optimal clinical benefit, according to data presented at EULAR 2014.
At EULAR 2014, new research showed that ultrasound-guided injections of growth factors-containing platelet-rich plasma (PRP) are no more effective than saline injection sin treating recently developed epicondylitis.
Obese patients with rheumatoid arthritis (RA) have higher disease activity scores (DAS) than non-obese patients, regardless of their disease stage, scientists presented at EULAR 2014.
Recent findings identify a correlation between the presence of biomarkers in the blood (micro RNAs [miRNAs]) and the development of severe osteoarthritis of the knee or hip joint, as presented at EULAR 2014.
New research showed that it is possible to successfully stop immunosuppressant therapy without triggering a flare for the majority of lupus patients in remission, as presented at EULAR 2014.
Auxilium Pharmaceuticals announced new data from its Phase 3 IMPRESS trials that evaluated Xiaflex for the treatment of Peyronie's disease at the 2014 Annual Meeting of the AUA.
DEKA Integrated Solutions has received FDA marketing approval for the DEKA Arm System, the first prosthetic arm that can perform multiple, simultaneous powered movements controlled by electrical signals from electromyogram (EMG) electrode in individuals with upper extremity amputations occurring at the shoulder joint, mid-upper arm, or mid-lower arm.
Nano Well-Being Health is issuing a voluntary recall of two lots of Super Arthgold 500mg capsules, a dietary supplement for joint pain and arthritis.
The FDA is warning patients and healthcare professionals about the potential for rare but serious adverse events associated with injection of corticosteroids into the epidural space of the spine.
Sarepta Therapeutics has announced its plans to submit a New Drug Application (NDA) for eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).
Antares Pharma announced the publication of results from its crossover study comparing the relative bioavailability, safety, and tolerability of Otrexup (methotrexate) to oral methotrexate (MTX) in adults with rheumatoid arthritis in the Annals of the Rheumatic Diseases.
ReCept announced that it is one of the specialty pharmacies selected to distribute Otezla (apremilast; Celgene), a recently approved drug for adults with active psoriatic arthritis.
Ampio announced results of the 20 weeks extension of the SPRING study of Ampion for the treatment of osteoarthritis of the knee (OAK).
A novel therapy that involves electrical stimulation of the spinal cord has resulted in four individuals with paraplegia now being able to voluntarily move previously paralyzed muscles
The FDA has approved Otezla (apremilast; Celgene) tablets for the treatment of adults with active psoriatic arthritis.
Among U.S. patients undergoing spinal fusion, the rates of allogeneic blood transfusion increased from 2000-2009, while predonated autologous blood transfusion rates decreased.
Eagle Pharmaceuticals announced that the FDA has accepted the NDA for Ryanodex (dantrolene sodium) and has granted a priority review classification for the treatment of malignant hyperthermia.
Same-day bilateral total knee arthroplasty (BTKA) is safe in rheumatoid arthritis (RA) patients.
Neuromuscular training of all young athletes is a cost-effective strategy for reducing the costs and morbidity associated with ACL injuries.
The incidence of head and neck injuries (HNIs) resulting from participation in extreme sports increased from 2000-2011.
For patients undergoing primary total knee replacement, surgical, radiographic, and demographic variables associated with postoperative pain have been identified in two studies.
There is a substantially high rate of repeat spine imaging when patients with known spinal injuries are transferred from an outside hospital to a tertiary receiving institution.
Multiple 60-minute massage sessions are effective for neck dysfunction and pain among patients with chronic neck pain.
Oral glucosamine supplementation is not associated with a decrease in knee cartilage deterioration among individuals with chronic knee pain.
Pain Free By Nature announced a recall of Reumofan Plus Tablets because they were found to contain the following undeclared active ingredients: methocarbamol and diclofenac.
An estimated 4.5 million people are living with an artificial hip, and 6.7 million people in the United States are currently living with an artificial knee.
Receipt of a primary elective knee or hip total joint arthroplasty (TJA) for osteoarthritis (OA) provides a cardiovascular protective benefit.
Nonagenarian patients can safely undergo a total hip arthroplasty (THA), according to a recent study.
Patients undergoing lumbar spine surgery at teaching hospitals incur longer hospitalizations and have more postoperative complications compared to those treated at nonteaching hospitals.
Purdue Pharma announced results from a Phase 3 study of an extended-release formulation of hydrocodone bitartrate in patients with chronic low back pain.
Scientists can predict who will respond to NSAID treatment by assessing the nervous system's own capacity to regulate pain
- Positive Phase 3 Results for Plecanatide in Chronic Idiopathic Constipation
- Dactinomycin Nanoparticle Formulation Receives Orphan Drug Designation
- Amphetamine XR-ODT NDA Resubmitted for ADHD Treatment
- ACP Supports Eliminating Non-Medical Exemptions for Immunizations
- Continuous, Intermittent β-Lactams Equally Effective in Sepsis